GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharnext SA (XPAR:ALPHA) » Definitions » Notes Receivable

Pharnext (XPAR:ALPHA) Notes Receivable : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Pharnext Notes Receivable?

Pharnext's Notes Receivable for the quarter that ended in Dec. 2023 was €0.00 Mil.


Pharnext Notes Receivable Historical Data

The historical data trend for Pharnext's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharnext Notes Receivable Chart

Pharnext Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharnext Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Pharnext Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Pharnext Notes Receivable Related Terms

Thank you for viewing the detailed overview of Pharnext's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharnext (XPAR:ALPHA) Business Description

Traded in Other Exchanges
Address
11-13 Rue Rene Jacques, Issy-Les-Moulineaux, FRA, 92130
Pharnext SA is a biopharmaceutical company developing treatments targeting neurodegenerative diseases. The company also develop a Pleotherapy technology platform. Its product in the pipeline includes SYNGILITY; PXT3003 and PXT864. The company's only segment being research and development on new pharmaceutical therapies based on Pleotherapy.

Pharnext (XPAR:ALPHA) Headlines

No Headlines